Total Payments
$115,700
2024 Payments
$19,923
Companies
15
Transactions
88
Medicare Patients
1,113
Medicare Billing
$200,918
Payment Breakdown by Category
Consulting$53,784 (46.5%)
Other$50,637 (43.8%)
Travel$5,428 (4.7%)
Research$4,318 (3.7%)
Food & Beverage$1,423 (1.2%)
Education$109.90 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $53,784 | 24 | 46.5% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $44,207 | 18 | 38.2% |
| Honoraria | $6,430 | 5 | 5.6% |
| Travel and Lodging | $5,428 | 19 | 4.7% |
| Unspecified | $4,318 | 4 | 3.7% |
| Food and Beverage | $1,423 | 16 | 1.2% |
| Education | $109.90 | 2 | 0.1% |
Payments by Type
General
$111,382
84 transactions
Research
$4,318
4 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Alexion Pharmaceuticals, Inc. | $54,341 | 36 | $0 (2024) |
| Apellis Pharmaceuticals, Inc. | $22,363 | 22 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $10,334 | 10 | $0 (2024) |
| Taiho Oncology, Inc. | $5,938 | 3 | $0 (2021) |
| Genentech, Inc. | $5,846 | 3 | $0 (2023) |
| E.R. Squibb & Sons, L.L.C. | $5,536 | 1 | $0 (2022) |
| Agios Pharmaceuticals, Inc. | $3,840 | 2 | $0 (2019) |
| Gilead Sciences, Inc. | $2,270 | 1 | $0 (2020) |
| BioCryst Pharmaceuticals, Inc. | $2,000 | 3 | $0 (2021) |
| Genentech USA, Inc. | $1,520 | 1 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $19,923 | 18 | Apellis Pharmaceuticals, Inc. ($6,856) |
| 2023 | $42,427 | 29 | Alexion Pharmaceuticals, Inc. ($26,164) |
| 2022 | $26,767 | 25 | Alexion Pharmaceuticals, Inc. ($13,486) |
| 2021 | $14,038 | 8 | Alexion Pharmaceuticals, Inc. ($5,500) |
| 2020 | $7,895 | 4 | Alexion Pharmaceuticals, Inc. ($3,750) |
| 2019 | $4,651 | 4 | Agios Pharmaceuticals, Inc. ($3,840) |
All Payment Transactions
88 individual payment records from CMS Open Payments — Page 1 of 4
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/06/2024 | GlaxoSmithKline, LLC. | OJJAARA (Drug) | Food and Beverage | In-kind items and services | $94.96 | General |
| Category: ONCOLOGY | ||||||
| 11/27/2024 | Regeneron Pharmaceuticals, Inc. | VEOPOZ (Biological) | — | Cash or cash equivalent | $1,310.00 | Research |
| Study: A Randomized, Open-Label, C5 Inhibitor-Controlled Study to Evaluate the Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy in Patients With Paroxysmal Nocturnal Hemoglobinuria Who Are Complement Inhibitor Treatment-Naive or Have Not Recently Received Complement Inhibitor Therapy • Category: RARE DISEASES | ||||||
| 11/21/2024 | Apellis Pharmaceuticals, Inc. | Empaveli (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,565.00 | General |
| Category: Hematology | ||||||
| 10/24/2024 | Apellis Pharmaceuticals, Inc. | Empaveli (Drug) | Travel and Lodging | In-kind items and services | $1,110.94 | General |
| Category: Hematology | ||||||
| 10/24/2024 | Apellis Pharmaceuticals, Inc. | Empaveli (Drug) | Food and Beverage | In-kind items and services | $107.73 | General |
| Category: Hematology | ||||||
| 09/30/2024 | Alexion Pharmaceuticals, Inc. | SOLIRIS (Biological) | Consulting Fee | Cash or cash equivalent | $3,100.00 | General |
| Category: Rare Disease | ||||||
| 08/29/2024 | Novartis Pharmaceuticals Corporation | Fabhalta (Drug) | Consulting Fee | Cash or cash equivalent | $675.00 | General |
| Category: Immunology | ||||||
| 08/01/2024 | Novartis Pharmaceuticals Corporation | — | — | Cash or cash equivalent | $396.11 | Research |
| Study: CLNP023C12302 - APPLY-PNH | ||||||
| 08/01/2024 | Novartis Pharmaceuticals Corporation | — | — | Cash or cash equivalent | $254.64 | Research |
| Study: CLNP023C12302 - APPLY-PNH, CLNP023C12301 - APPOINT-PNH | ||||||
| 07/18/2024 | Genentech USA, Inc. | — | Consulting Fee | Cash or cash equivalent | $1,520.00 | General |
| 05/29/2024 | Novartis Pharmaceuticals Corporation | — | Consulting Fee | Cash or cash equivalent | $2,700.00 | General |
| 05/29/2024 | Novartis Pharmaceuticals Corporation | — | Travel and Lodging | In-kind items and services | $309.46 | General |
| 05/29/2024 | Novartis Pharmaceuticals Corporation | — | Travel and Lodging | Cash or cash equivalent | $259.00 | General |
| 05/29/2024 | Novartis Pharmaceuticals Corporation | — | Travel and Lodging | In-kind items and services | $72.00 | General |
| 05/29/2024 | Novartis Pharmaceuticals Corporation | — | Food and Beverage | In-kind items and services | $35.00 | General |
| 05/01/2024 | Apellis Pharmaceuticals, Inc. | Empaveli (Drug) | Food and Beverage | In-kind items and services | $72.67 | General |
| Category: Hematology | ||||||
| 04/16/2024 | Apellis Pharmaceuticals, Inc. | Empaveli (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,000.00 | General |
| Category: Hematology | ||||||
| 01/10/2024 | Alexion Pharmaceuticals, Inc. | ULTOMIRIS (Biological) | Consulting Fee | Cash or cash equivalent | $2,340.00 | General |
| Category: Rare Disease | ||||||
| 12/11/2023 | Apellis Pharmaceuticals, Inc. | Empaveli (Drug) | Food and Beverage | Cash or cash equivalent | $21.33 | General |
| Category: Hematology | ||||||
| 12/10/2023 | Celgene Corporation | REBLOZYL (Biological) | Food and Beverage | Cash or cash equivalent | $110.71 | General |
| Category: Hematology | ||||||
| 10/27/2023 | Genentech, Inc. | — | Consulting Fee | Cash or cash equivalent | $5,320.00 | General |
| 10/27/2023 | Genentech, Inc. | — | Travel and Lodging | Cash or cash equivalent | $381.33 | General |
| 10/27/2023 | Genentech, Inc. | — | Travel and Lodging | Cash or cash equivalent | $144.99 | General |
| 10/24/2023 | Alexion Pharmaceuticals, Inc. | — | Consulting Fee | Cash or cash equivalent | $9,360.00 | General |
| 09/28/2023 | Alexion Pharmaceuticals, Inc. | ULTOMIRIS (Biological) | Travel and Lodging | Cash or cash equivalent | $56.18 | General |
| Category: Rare Disease | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| CLNP023C12302 | Novartis Pharmaceuticals Corporation | $2,358 | 1 |
| A Randomized, Open-Label, C5 Inhibitor-Controlled Study to Evaluate the Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy in Patients With Paroxysmal Nocturnal Hemoglobinuria Who Are Complement Inhibitor Treatment-Naive or Have Not Recently Received Complement Inhibitor Therapy | Regeneron Pharmaceuticals, Inc. | $1,310 | 1 |
| CLNP023C12302 - APPLY-PNH | Novartis Pharmaceuticals Corporation | $396.11 | 1 |
| CLNP023C12302 - APPLY-PNH, CLNP023C12301 - APPOINT-PNH | Novartis Pharmaceuticals Corporation | $254.64 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 4 | 194 | 415 | $158,848 | $32,881 |
| 2022 | 6 | 272 | 719 | $313,761 | $57,369 |
| 2021 | 5 | 357 | 779 | $351,568 | $67,862 |
| 2020 | 8 | 290 | 641 | $289,880 | $42,805 |
Total Patients
1,113
Total Services
2,554
Medicare Billing
$200,918
Procedure Codes
25
All Medicare Procedures & Services
25 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 111 | 229 | $80,360 | $14,424 | 17.9% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 43 | 80 | $36,628 | $7,982 | 21.8% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 20 | 86 | $30,100 | $7,844 | 26.1% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 20 | 20 | $11,760 | $2,631 | 22.4% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 41 | 273 | $95,550 | $20,736 | 21.7% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 116 | 254 | $113,284 | $15,866 | 14.0% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 69 | 141 | $76,566 | $14,630 | 19.1% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 17 | 20 | $13,560 | $3,034 | 22.4% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 16 | 16 | $10,976 | $2,265 | 20.6% |
| 99238 | Hospital discharge day management, 30 minutes or less | Facility | 2022 | 13 | 15 | $3,825 | $837.91 | 21.9% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 45 | 272 | $95,200 | $22,175 | 23.3% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 82 | 171 | $92,484 | $18,955 | 20.5% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Facility | 2021 | 60 | 112 | $60,704 | $10,233 | 16.9% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 83 | 127 | $56,642 | $9,498 | 16.8% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 22 | 24 | $16,272 | $3,670 | 22.6% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 53 | 61 | $27,206 | $2,647 | 9.7% |
| 99238 | Hospital discharge day management, 30 minutes or less | Facility | 2021 | 12 | 12 | $3,060 | $685.02 | 22.4% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Facility | 2020 | 146 | 371 | $165,466 | $19,751 | 11.9% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2020 | 31 | 148 | $51,800 | $12,211 | 23.6% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2020 | 20 | 21 | $14,238 | $3,171 | 22.3% |
| 99205 | New patient office or other outpatient visit, typically 60 minutes | Facility | 2020 | 27 | 27 | $18,522 | $3,054 | 16.5% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Facility | 2020 | 29 | 34 | $18,428 | $2,608 | 14.2% |
| 38222 | Bone marrow biopsy and aspiration | Facility | 2020 | 13 | 13 | $14,079 | $790.96 | 5.6% |
| 99238 | Hospital discharge day management, 30 minutes or less | Facility | 2020 | 13 | 13 | $3,315 | $753.16 | 22.7% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Facility | 2020 | 11 | 14 | $4,032 | $466.78 | 11.6% |
About Dr. Carlos Decastro, M.D
Dr. Carlos Decastro, M.D is a Hematology & Oncology healthcare provider based in Durham, North Carolina. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 10/23/2006. The National Provider Identifier (NPI) number assigned to this provider is 1912080169.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Carlos Decastro, M.D has received a total of $115,700 in payments from pharmaceutical and medical device companies, with $19,923 received in 2024. These payments were reported across 88 transactions from 15 companies. The most common payment nature is "Consulting Fee" ($53,784).
As a Medicare-enrolled provider, Decastro has provided services to 1,113 Medicare beneficiaries, totaling 2,554 services with total Medicare billing of $200,918. Data is available for 4 years (2020–2023), covering 25 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Location Durham, NC
- Active Since 10/23/2006
- Last Updated 08/13/2013
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1912080169
Products in Payments
- ULTOMIRIS (Biological) $26,821
- Empaveli (Drug) $22,363
- Ultomiris (Drug) $6,750
- INQOVI (Drug) $4,063
- TIBSOVO (Drug) $3,840
- SOLIRIS (Biological) $3,100
- VEOPOZ (Biological) $1,310
- Fabhalta (Drug) $675.00
- REBLOZYL (Biological) $197.36
- OJJAARA (Drug) $94.96
- BESPONSA (Biological) $10.90
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in Durham
Michael Morse, M.d, M.D
Hematology & Oncology — Payments: $2.8M
Hematology & Oncology $2.8M
Cristina Gasparetto, M.d, M.D
Hematology & Oncology — Payments: $765,745
Hematology & Oncology $765,745
Phillip Febbo, M.d, M.D
Hematology & Oncology — Payments: $751,716
Hematology & Oncology $751,716
Ivy Altomare, Md, MD
Hematology & Oncology — Payments: $369,810
Hematology & Oncology $369,810
Jeffrey Crawford, M.d, M.D
Hematology & Oncology — Payments: $273,264
Hematology & Oncology $273,264
Dr. Matthew Mckinney, M.d, M.D
Hematology & Oncology — Payments: $259,140
Hematology & Oncology $259,140